No quarterly revenue total was found in METAVIA INC.'s SEC filings.
Metavia Inc. (MTVA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $12.6 million in cash and investments and $177,000 in total debt.
Revenue
—
Net income
$-5.32M
-33.1% vs year-ago quarter
Operating cash flow
$-3.76M
-22.5% vs year-ago quarter
Free cash flow
$-4.86M
+11.1% vs year-ago quarter
EPS
$-0.90
+68.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
6.59M
-72.8% vs year-ago quarter
Net cash
$12.46M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MTVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1638287
- Former names
- NeuroBo Pharmaceuticals, Inc. (until Nov 18, 2024); Gemphire Therapeutics Inc. (until Dec 31, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.4M | -$4.0M | -$2.0M | -$3.5M | -$4.3M |
| Net income | -$5.3M | -$3.8M | -$1.9M | -$3.4M | -$4.0M |
| Diluted EPS | -$0.90 | -$0.79 | $0.04 | -$0.14 | -$2.87 |
| Operating cash flow | -$3.8M | -$4.3M | -$4.9M | -$3.0M | -$3.1M |
| Free cash flow | — | — | -$4.9M | -$3.0M | -$3.1M |
| Total assets | $13.3M | $14.4M | $11.1M | $14.8M | $18.5M |
| Total liabilities | $6.4M | $5.3M | $5.8M | $8.4M | $8.8M |
| Stockholders' equity | $6.8M | $9.1M | $5.3M | $6.3M | $9.6M |
| Cash and investments | $12.6M | $13.7M | $10.3M | $14.3M | $17.6M |
| Total debt | $177,000 | $194,000 | $210,000 | $79,000 | $98,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
All 633 Metavia Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.